Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MitoQ versus placebo in early septic shock
IRCT20120215009014N500Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Apr 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in septic shock comparing MitoQ with Placebo (2 arms). Primary endpoint: Serum oxidative stress biomarkers. Started Apr 2024; status: completed.
02
Drugs
mitoquinone
03
Conditions
septic shock
Beyond the preview
Go deeper on IRCT20120215009014N500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120215009014N500.